Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Massimo Lombardi,
The exclusive added value of CMR is the capability to assess pathologic aspects of myocardial tissue such as myocardial oedema and increased blood volume due to vasodilatation and areas of myocardial necrosis/fibrosis. An overall diagnostic accuracy of 78% can be achieved in the diagnosis of myocarditis using CMR.
Myocarditis has been reported in up to 12% of young adults presenting with sudden death and is an important underlying etiology of other myocardial diseases such as dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.
The incidence of nonfatal miocarditis is probably greater than actually diagnosed. Direct viral infection or post-viral immune-mediated reaction is likely the most common cause of myocarditis but toxic, mechanical injury, drug related inflammation, transplant rejection, etc., can also sustain the inflammatory status.
Although the molecular and cellular pathophysiology may differ between the different aetiologies, cellular infiltration, necrosis, oedema and fibrotic scars are common features. Endomyocardial biopsy (histopathology, immunohistology and molecular techniques to identify viral genomes) is a widely accepted method for diagnosing miocarditis. However endomyocardial biopsy suffers limited sensitivity, the occurence of complications (severe or trivial complications in up 6% of patients) and poor overall inter-observer agreement when applying diagnostic criteria to endomyocardial specimens.
Several papers have studied the diagnostic utility of non-contrast and contrast enhanced CMR in patients with suspected or confirmed myocarditis. Although the lack of large and controlled multicenter trials still prevent us from considering this technology as first choice imaging technique, several reports underline the clinical suitability of CMR in patients with clinical suspected myocarditis.
Diagnostic targets for CMR include Left Ventricle regional and global function and morphological abnormalities such as transient increase of ventricular volumes and mass. Other pathologic abnormalities of which pericardial effusion can be easily detected. The exclusive added value of CMR is the capability to assess pathologic aspects of myocardial tissue as diagnostic features of inflammation. Oedema is an important hallmark of inflammatory cell injury and T2-weighted images sensitively detects tissue oedema. The presence of high signal intensity of oedematous tissue can be easily differentiated from normal darker tissue. In the rare case where an homogeneous oedematous myocardium is present, a more sophisticated post processing approach needs to be adopted. Furthermore, early on after the injection of contrast agent (two-three minutes) an signal increase can be detected as a marker of increased blood volume in the inflamed area due to regional vasodilatation. Furthermore, the Late Gadolinium Enhancement (LGE) technique specifically reflects irreversible myocardial injury (i.e. necrosis and fibrosis) in the acute phase (acute injured cell membranes) but also in the chronic phase after the inflammatory clearance of necrotic regions (fibromyocytes and large interstitial fibrotic deposits). If all the three markers of myocardial inflammation are used, a Positive Predictive Value of 91% a Negative Predictive Value of 69% and a Diagnostic Accuracy of 78% have been shown.
Cases of reduced sensitiveness of CMR when performed too early (within 7 days) after the onset of symptoms have been reported. This may be due to the focal nature of the early stage of the disease. Furthermore pilot data indicate a prognostic relevance of persisting CMR markers for inflammation at 4 weeks after onset. Thus the decision regarding folow-up of patients with suspected or proven active myocarditis depends on the individual scenario. To summarise:
Fig.1 Patient with recent episode of chest pain and fever. Slight increase in Troponin, ECG inconclusive, normal coronary arteries. At CMR evidence of small areas of Myocardial oedema (arrow). Images obtained by Triple Inversion Recovery technique. Fig. 2 Patient with clinical features of myocarditis in the past (10 weeks before the CMR study). Normal coronary arteries. At CMR evidence of small areas of fibro-necrosis (arrows). Images obtained using Late Gadolinium Enhancement technique.
The use of CMR appears suitable to identify patients with ongoing inflammation. All the tissue markers of inflammation should be evaluated during the CMR study in a patients with suspected myocarditis
Furthermore left ventricle regional and global function as well as the presence/absence of pericardial effusion need to be assessed. Lasty, the correct scheduling for CMR exams to take place is to be evaluated either in the acute phase or during follow-up.
Frieddrich MG, Sechtem U, Shulz-Menger J, Holmvang G, Alakija P, Cooper L.T., White JA, Abdel-Aty H, Gutberled M, Prasad S, Aletras A, Laissy J-P, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P. Cardiovascular Magnetic Resonance in Myocarditis: a JACC White Paper. J Am Coll Cardiol 2009;53;17:1475-1487.
© 2017 European Society of Cardiology. All rights reserved